Free-cash-flow proxy decreased 7.0%
Free-cash-flow proxy changed -7.0% from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
$508.0M→$472.4M3 prior comparisons
GROSSPATTERN / DETERMINISTIC EVIDENCE / V3
Search securities →ZM financial changes
Ranked by interpretable importance, issuer history, magnitude, and accounting profile. No directional recommendation.
Free-cash-flow margin moved 475 bp lower
Free-cash-flow margin changed -475 basis points from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
41.73%→36.99%2 prior comparisons
Operating cash flow decreased 4.1%
Operating cash flow changed -4.1% from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
$515.9M→$494.8M3 prior comparisons
Operating cash flow / net income decreased 77.7%
Operating cash flow / net income changed -77.7% from the comparable as-filed period.
1.44→0.322 prior comparisons
Operating cash-flow margin moved 365 bp lower
Operating cash-flow margin changed -365 basis points from the comparable as-filed period.
42.39%→38.74%2 prior comparisons
Revenue increased 4.9%
Revenue changed +4.9% from the comparable as-filed period.
$1.2B→$1.3B2 prior comparisons
SBC / revenue moved 143 bp lower
SBC / revenue changed -143 basis points from the comparable as-filed period.
15.50%→14.08%2 prior comparisons
Research & development increased 17.5%
Research & development changed +17.5% from the comparable as-filed period.
$206.4M→$242.5M2 prior comparisons
Operating income decreased 2.3%
Operating income changed -2.3% from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
$321.7M→$314.3M2 prior comparisons
Gross margin moved 40 bp lower
Gross margin changed -40 basis points from the comparable as-filed period.
77.56%→77.16%2 prior comparisons
Current assets decreased 6.3%
Current assets changed -6.3% from the comparable as-filed period. The change ranks at the 50th percentile of 4 prior comparable changes.
$8.7B→$8.1B4 prior comparisons
Capex / revenue moved 110 bp higher
Capex / revenue changed +110 basis points from the comparable as-filed period.
0.65%→1.75%2 prior comparisons
R&D / revenue moved 203 bp higher
R&D / revenue changed +203 basis points from the comparable as-filed period.
16.96%→18.99%2 prior comparisons
Gross profit increased 4.4%
Gross profit changed +4.4% from the comparable as-filed period.
$944.1M→$985.5M2 prior comparisons
Receivables / revenue moved 73 bp lower
Receivables / revenue changed -73 basis points from the comparable as-filed period.
42.46%→41.73%2 prior comparisons
Stock-based compensation decreased 4.7%
Stock-based compensation changed -4.7% from the comparable as-filed period.
$188.7M→$179.8M2 prior comparisons
Trade receivables increased 3.1%
Trade receivables changed +3.1% from the comparable as-filed period. The change ranks at the 50th percentile of 4 prior comparable changes.
$516.8M→$533.0M4 prior comparisons
Method Importance combines metric-family relevance, magnitude, issuer-history unusualness, persistence, and financial-statement significance. It is analytical prioritization, not a legal materiality conclusion or investment signal.